FDA Clearance Tracker · P050052-S081
RADIESSE INJECTABLE IMPLANT
Last checked: Nov 20, 2026Latest source record: Jan 20, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Jan 20, 2016
Approved
Time to decision
40 days
Received Dec 11, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P050052-S081
- Device name
- RADIESSE INJECTABLE IMPLANT
- Applicant
- Merz North America, Inc.
- Applicant location
- Franksville, WI
- Received
- Dec 11, 2015
- Decided
- Jan 20, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol - OSB
- Original approval
- P050052
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
APPROVAL OF THE FOLLOWING CHANGES TO THE POST-APPROVAL STUDY FOR THE DEVICE:REVISIONS TO THE PATIENT DIARY, ENROLLMENT FORM AND RADIOLOGY FORM.
Source documents
Other decisions for Merz North America, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250016 · Decided Jul 9, 2026 · 387 days after receipt
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
6 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.